RBPJK抗体;RBPJK Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of RBPJK expression in MCF7 cell lysate.    

  
  

The Recombination Signal Binding Protein for Immunoglobulin Kappa J Region (RBPJκ), also known as CBF1 or CSL, is a conserved transcription factor critical for mediating Notch signaling, an evolutionarily conserved pathway regulating cell differentiation, proliferation, and survival. RBPJκ acts as a central DNA-binding component, interacting with Notch receptors’ intracellular domains (NICD) upon ligand activation. This interaction displaces co-repressors and recruits co-activators (e.g., Mastermind-like proteins) to modulate target gene expression, including *Hes* and *Hey* families.

RBPJκ antibodies are essential tools for studying Notch pathway dynamics. They enable detection of RBPJκ expression, localization (nuclear vs. cytoplasmic), and protein-protein/DNA interactions via techniques like Western blot, immunofluorescence, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assays (EMSA). These antibodies help investigate RBPJκ’s roles in development, stem cell maintenance, and diseases such as cancer (e.g., T-cell leukemia, breast cancer), cardiovascular disorders, and neurological conditions.

Validated RBPJκ antibodies (monoclonal/polyclonal) are crucial for specificity, often confirmed using RBPJκ-knockout controls. Commercial antibodies vary in host species (rabbit, mouse), epitope targets (N-terminal, C-terminal), and applications (e.g., IP-specific clones). Researchers prioritize antibodies with published data in their experimental models to ensure reliability. Dysregulated RBPJκ/Notch signaling is a therapeutic target, underscoring the antibody’s relevance in mechanistic and translational studies.